Drugs / 177Lu-DOTA-JR11
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04997317 Comparator | Apr 2021 → Dec 2026 expected | meningioma | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DOTA-JR11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04997317 ↗ |
| Known as | [177Lu]Lu-DOTA-JR11 | “Our primary aim was to compare the therapeutic index (tumor-to-bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin receptor antagonist...” PMID 38423782 ↗ Apr 2024 |
| Route | Intravenous | “177Lu-DOTA-JR11 will be administered once intravenously” NCT04997317 ↗ |